Conclusions
SARS-Cov-2 has highlighted even more the serious safety problems of drugs for MS especially with regard to new immunomodulatory drugs with increased potential risks of infection. Is it safe to continue therapy during the pandemic? Based on the evidence in the literature, the position of the agencies in the different countries and given the complexity of the treatment of MS the best thing is that the decision is based on the individual condition of the patient. It is useless to hide that the therapy must be even more personalized and the patient carefully monitored. MS needs to be treated avoiding infection risks: the doctor’s job is to maintain this balance by ensuring the greatest possible safety. Depletive therapies, which significantly affect the patient’s immune system, safely lead to a decrease in lymphocytes and an associated risk of infection. However, failure to take therapies can lead the patient to have new disease attacks and for this there is no reason to stop without proven need. It is important to follow national and international guidelines and the positions of scientific societies and regulatory agencies because the therapy must be personalized as much as possible according to the clinical picture. Important for this is constant monitoring.